health · source
STAT News on WeSearch
Recent health headlines from STAT News.
STAT
Nonprofit buys experimental cancer drug to maintain patient access
STAT
Study highlights influence of socioeconomic status on children’s brain development
STAT
STAT+: Abridge inks deals with Nvidia and Lilly
STAT
STAT+: Novartis doubles down on molecular glue strategy
STAT
Opinion: We published in Nature Medicine in 2025 for free. In 2026, it cost us $12,850
STAT
Opinion: How long Covid’s scientific stalemate made it politically erasable
STAT
STAT+: Scientists see promise in NIH proposal to cap number of grants they receive
STAT
STAT+: Private Medicare plans erect barriers to rehab care in pursuit of profit, federal investigators find
STAT
STAT+: Pharmalittle: We’re reading about U.S. pressure on European drug prices, longer shortages, and more
STAT
Are Republicans turning against medications for treating opioid addiction?
STAT
Opinion: ‘They all think I’m insane’: What it’s like to start medical residency at 72
STAT
STAT+: As the U.S. looks on, European countries feel growing pressure on drug prices
STAT
Opinion: Even in abortion-protecting states, teens face unnecessary barriers to care
STAT
Dexcom RCT suggests CGM benefits for broad diabetes population
STAT
STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
STAT
STAT+: NIH staffers published a letter of dissent a year ago. They feel it’s been ignored
STAT
STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
STAT
STAT+: Novo underwhelmed by drug it once fought Pfizer for
STAT
STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
STAT
Opinion: How the Amish think about vaccines, health care costs, and much more
STAT
Opinion: I led the U.S. CDC response to the 2014 Ebola epidemic. The new outbreak needs massive, immediate, meticulous action
STAT
STAT+: Newer GLP-1s, pushback on research cuts, and a protest
STAT
STAT+: Up and down the ladder: The latest comings and goings
STAT
STAT+: Will Makary’s FDA voucher program survive?
STAT
STAT+: Drug companies, patient groups urge FDA to pause commissioner’s voucher program
STAT
What happens at a longevity festival?
STAT
Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this story
STAT
Opinion: Lawmakers promised cancer patients would be protected from Medicaid cuts. Now CMS says otherwise
STAT
Male puberty is understudied — but when it starts may predict long-term health risks
STAT
STAT+: After hospitals, patients get a turn to bring AI into the doctor’s office
STAT
STAT+: What the pope’s encyclical on AI means for Catholic hospitals, and all of health care
STAT NEWS
STAT+: Legend Biotech emerged as a rare market winner
STAT
Opinion: The Amish way of health care
STAT
Opinion: The medical-billing AI arms race between providers and insurance
STAT
Opinion: How the military may be fueling eating disorders in men
STAT
STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patients
STAT
STAT+: NIH cuts weakened network primed to respond to outbreaks like Ebola
STAT
Top ultra-processed food researchers call for sweeping policy change: ‘The system is rigged’
STAT
STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and more
STAT
How one state’s medical meal program lowered health care costs
STAT
STAT+: Eli Lilly warns hospitals to submit claims data in the next five days or lose their 340B drug discounts
STAT
As FDA misses deadline on electric shock ban, disability advocates speak out
STAT
Opinion: What should hospitals do when patients demand unvaccinated donor blood?
STAT
STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
STAT
CDC says containing the spread of Ebola is top priority
STAT
STAT+: A turning point for pancreatic cancer patients
STAT
STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
STAT
STAT+: A standing ovation for RevMed, and caution for Akeso
STAT
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
STAT